Literature DB >> 21545414

Endocannabinoid tone versus constitutive activity of cannabinoid receptors.

Allyn C Howlett1, Patricia H Reggio, Steven R Childers, Robert E Hampson, Nadine M Ulloa, Dale G Deutsch.   

Abstract

This review evaluates the cellular mechanisms of constitutive activity of the cannabinoid (CB) receptors, its reversal by inverse agonists, and discusses the pitfalls and problems in the interpretation of the research data. The notion is presented that endogenously produced anandamide (AEA) and 2-arachidonoylglycerol (2-AG) serve as autocrine or paracrine stimulators of the CB receptors, giving the appearance of constitutive activity. It is proposed that one cannot interpret inverse agonist studies without inference to the receptors' environment vis-à-vis the endocannabinoid agonists which themselves are highly lipophilic compounds with a preference for membranes. The endocannabinoid tone is governed by a combination of synthetic pathways and inactivation involving transport and degradation. The synthesis and degradation of 2-AG is well characterized, and 2-AG has been strongly implicated in retrograde signalling in neurons. Data implicating endocannabinoids in paracrine regulation have been described. Endocannabinoid ligands can traverse the cell's interior and potentially be stored on fatty acid-binding proteins (FABPs). Molecular modelling predicts that the endocannabinoids derived from membrane phospholipids can laterally diffuse to enter the CB receptor from the lipid bilayer. Considering that endocannabinoid signalling to CB receptors is a much more likely scenario than is receptor activation in the absence of agonist ligands, researchers are advised to refrain from assuming constitutive activity except for experimental models known to be devoid of endocannabinoid ligands.
© 2011 The Authors. British Journal of Pharmacology © 2011 The British Pharmacological Society.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21545414      PMCID: PMC3165945          DOI: 10.1111/j.1476-5381.2011.01364.x

Source DB:  PubMed          Journal:  Br J Pharmacol        ISSN: 0007-1188            Impact factor:   8.739


  137 in total

1.  High-resolution crystal structure of an engineered human beta2-adrenergic G protein-coupled receptor.

Authors:  Vadim Cherezov; Daniel M Rosenbaum; Michael A Hanson; Søren G F Rasmussen; Foon Sun Thian; Tong Sun Kobilka; Hee-Jung Choi; Peter Kuhn; William I Weis; Brian K Kobilka; Raymond C Stevens
Journal:  Science       Date:  2007-10-25       Impact factor: 47.728

2.  Small angle x-ray diffraction studies on the topography of cannabinoids in synaptic plasma membranes.

Authors:  T Mavromoustakos; D P Yang; W Broderick; D Fournier; A Makriyannis
Journal:  Pharmacol Biochem Behav       Date:  1991-11       Impact factor: 3.533

3.  Activation of mitogen-activated protein kinases by stimulation of the central cannabinoid receptor CB1.

Authors:  M Bouaboula; C Poinot-Chazel; B Bourrié; X Canat; B Calandra; M Rinaldi-Carmona; G Le Fur; P Casellas
Journal:  Biochem J       Date:  1995-12-01       Impact factor: 3.857

4.  Depolarization-induced suppression of GABAergic inhibition in rat hippocampal pyramidal cells: G protein involvement in a presynaptic mechanism.

Authors:  T A Pitler; B E Alger
Journal:  Neuron       Date:  1994-12       Impact factor: 17.173

5.  Structure of bovine rhodopsin in a trigonal crystal form.

Authors:  Jade Li; Patricia C Edwards; Manfred Burghammer; Claudio Villa; Gebhard F X Schertler
Journal:  J Mol Biol       Date:  2004-11-05       Impact factor: 5.469

6.  Crystal structure of the human beta2 adrenergic G-protein-coupled receptor.

Authors:  Søren G F Rasmussen; Hee-Jung Choi; Daniel M Rosenbaum; Tong Sun Kobilka; Foon Sun Thian; Patricia C Edwards; Manfred Burghammer; Venkata R P Ratnala; Ruslan Sanishvili; Robert F Fischetti; Gebhard F X Schertler; William I Weis; Brian K Kobilka
Journal:  Nature       Date:  2007-10-21       Impact factor: 49.962

7.  Inhibitors of arachidonoyl ethanolamide hydrolysis.

Authors:  B Koutek; G D Prestwich; A C Howlett; S A Chin; D Salehani; N Akhavan; D G Deutsch
Journal:  J Biol Chem       Date:  1994-09-16       Impact factor: 5.157

8.  Isolation and structure of a brain constituent that binds to the cannabinoid receptor.

Authors:  W A Devane; L Hanus; A Breuer; R G Pertwee; L A Stevenson; G Griffin; D Gibson; A Mandelbaum; A Etinger; R Mechoulam
Journal:  Science       Date:  1992-12-18       Impact factor: 47.728

9.  GPCR engineering yields high-resolution structural insights into beta2-adrenergic receptor function.

Authors:  Daniel M Rosenbaum; Vadim Cherezov; Michael A Hanson; Søren G F Rasmussen; Foon Sun Thian; Tong Sun Kobilka; Hee-Jung Choi; Xiao-Jie Yao; William I Weis; Raymond C Stevens; Brian K Kobilka
Journal:  Science       Date:  2007-10-25       Impact factor: 47.728

10.  Enzymatic synthesis and degradation of anandamide, a cannabinoid receptor agonist.

Authors:  D G Deutsch; S A Chin
Journal:  Biochem Pharmacol       Date:  1993-09-01       Impact factor: 5.858

View more
  44 in total

Review 1.  Triphasic blood pressure responses to cannabinoids: do we understand the mechanism?

Authors:  Barbara Malinowska; Marta Baranowska-Kuczko; Eberhard Schlicker
Journal:  Br J Pharmacol       Date:  2012-04       Impact factor: 8.739

2.  The Antinociceptive Agent SBFI-26 Binds to Anandamide Transporters FABP5 and FABP7 at Two Different Sites.

Authors:  Hao-Chi Hsu; Simon Tong; Yuchen Zhou; Matthew W Elmes; Su Yan; Martin Kaczocha; Dale G Deutsch; Robert C Rizzo; Iwao Ojima; Huilin Li
Journal:  Biochemistry       Date:  2017-06-28       Impact factor: 3.162

3.  Fatty acid-binding proteins (FABPs) are intracellular carriers for Δ9-tetrahydrocannabinol (THC) and cannabidiol (CBD).

Authors:  Matthew W Elmes; Martin Kaczocha; William T Berger; KwanNok Leung; Brian P Ralph; Liqun Wang; Joseph M Sweeney; Jeremy T Miyauchi; Stella E Tsirka; Iwao Ojima; Dale G Deutsch
Journal:  J Biol Chem       Date:  2015-02-09       Impact factor: 5.157

4.  Song-associated reward correlates with endocannabinoid-related gene expression in male European starlings (Sturnus vulgaris).

Authors:  Allison H Hahn; Devin P Merullo; Jeremy A Spool; Caroline S Angyal; Sharon A Stevenson; Lauren V Riters
Journal:  Neuroscience       Date:  2017-01-29       Impact factor: 3.590

5.  Themed issue on cannabinoids in biology and medicine.

Authors:  Itai Bab
Journal:  Br J Pharmacol       Date:  2011-08       Impact factor: 8.739

Review 6.  Modulation of CB1 cannabinoid receptor by allosteric ligands: Pharmacology and therapeutic opportunities.

Authors:  Leepakshi Khurana; Ken Mackie; Daniele Piomelli; Debra A Kendall
Journal:  Neuropharmacology       Date:  2017-05-17       Impact factor: 5.250

Review 7.  Cannabinoid receptors: nomenclature and pharmacological principles.

Authors:  Linda Console-Bram; Jahan Marcu; Mary E Abood
Journal:  Prog Neuropsychopharmacol Biol Psychiatry       Date:  2012-02-28       Impact factor: 5.067

8.  The Concise Guide to PHARMACOLOGY 2013/14: G protein-coupled receptors.

Authors:  Stephen P H Alexander; Helen E Benson; Elena Faccenda; Adam J Pawson; Joanna L Sharman; Michael Spedding; John A Peters; Anthony J Harmar
Journal:  Br J Pharmacol       Date:  2013-12       Impact factor: 8.739

9.  CB1 cannabinoid receptor-mediated increases in cyclic AMP accumulation are correlated with reduced Gi/o function.

Authors:  Khalil Eldeeb; Sandra Leone-Kabler; Allyn C Howlett
Journal:  J Basic Clin Physiol Pharmacol       Date:  2016-05-01

Review 10.  Endogenous cannabinoid signaling at inhibitory interneurons.

Authors:  Thomas J Younts; Pablo E Castillo
Journal:  Curr Opin Neurobiol       Date:  2013-12-28       Impact factor: 6.627

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.